Toggle Nav

PRT062607 Hydrochloride

In stock
Catalog No.
A3736
SYK inhibitor,potent and selective
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$130.00
In stock
Evaluation Sample
$28.00
In stock
5mg
$119.00
In stock
25mg
$285.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

PRT062607 Hydrochloride is a highly selective and novel SYK inhibitor with IC50 value of 1 nM. Spleen tyrosine kinase (SYK) is a cytoplasmic tyrosine kinase and primarily expressed in hematopoietic cells including B-cells.
PRT062607 Hydrochloride is an orally bioavailable SYK inhibitor and its affinity for SYK is at least 80-fold greater than other kinases. In NHL cell lines, PRT062607 Hydrochloride inhibits SYK activation and induces caspase dependent apoptosis. Also, PRT062607 Hydrochloride inhibited SYK and caused apoptosis of the tumor B-cell line [1].
PRT062607 Hydrochloride effectively antagonize CLL cell survival after BCR triggering. Moreover, they inhibit the secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell transfer toward beneath stromal cells, the tissue homing chemokines CXCL13 and CXCL12 [2].
In a mouse xenograft model, mice dosed with all three concentrations (twice daily with 10, 15, or 20 mg/kg) of  PRT062607 Hydrochloride were protected from Ramos tumor growth [1].
References:
[1]. Spurgeon SE, Coffey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther, 2013, 344(2): 378-387.
[2]. Hoellenriegel J, Coffey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia, 2012, 26(7): 1576-1583.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt429.91
Cas No.1370261-97-4
FormulaC19H24ClN9O
SynonymsPRT 062607 hydrochloride;PRT-062607 hydrochloride
Solubility≥21.5 mg/mL in DMSO, <2.81 mg/mL in EtOH, ≥83.2 mg/mL in H2O with gentle warming
Chemical Name4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2R)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride
SDFDownload SDF
Canonical SMILESNC(C1=C(NC2=CC(N3N=CC=N3)=CC=C2)N=C(N[[email protected]]4[[email protected]](N)CCCC4)N=C1)=O.Cl
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment: [1]

Cell lines

Primary B-cells, SU-DHL6 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

1 μM, 24 hours

Applications

To compare the relative sensitivity of primary versus tumor B-cells, the mixing experiments in which SU-DHL6 was combined with human whole blood and treated with P505-15 were performed. Under these conditions, whereas the tumor B-cell line underwent apoptosis in response to SYK inhibition, primary B-cells did not.

Animal experiment: [1]

Animal models

NOD/SCID mice injected with Ramos cells

Dosage form

Oral administration, 10, 15, or 20 mg/kg, twice daily

Applications

A statistically significant reduction in average tumor weight was achieved in all dosing groups relative to vehicle control. It revealed that submicromolar concentrations of P505-15 prevented tumor formation by an aggressive NHL cell line in mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Spurgeon S E, Coffey G, Fletcher L B, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. Journal of Pharmacology and Experimental Therapeutics, 2013, 344(2): 378-387.

Biological Activity

Description PRT062607 (P505-15) HCl is a novel, highly selective inhibitor of Syk with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
Targets Syk Fgr MLK1      
IC50 1 nM 81 nM 88 nM      

Quality Control

Chemical structure

PRT062607 Hydrochloride

Related Biological Data

PRT062607 Hydrochloride